Artemisine MedicinesThe hidden killer in the supply chain
A malaria medicine that contains too little active ingredient — or none at all — does not just fail the patient in front of you. It exposes parasites to sub-lethal drug levels, the exact condition that breeds resistance and threatens the medicines everyone else depends on. WHO's malaria guideline therefore treats drug quality as a core treatment issue, not an administrative detail.
Three layers of protection
- GMP manufacturing: Good Manufacturing Practice means every batch is produced and tested under a documented quality system — raw-material control, in-process checks, finished-product release testing, and retained samples kept beyond expiry for investigation.
- Batch documentation: a Certificate of Analysis per batch proves this specific lot met specification; COPP, DMF and CTD dossiers let your regulator verify the product and site.
- WHO prequalification (PQ): an independent WHO review of the product's quality, safety and efficacy dossier plus site inspection. Global Fund and many national tenders either require PQ or accept it as fast-track evidence.
A practical quality checklist for buyers
- Ask for the manufacturing site's GMP evidence and most recent inspection outcome.
- Require a batch COA with every shipment — not a generic certificate.
- Confirm retained-sample and stability programs exist (retention one year past expiry is a good benchmark).
- For tender readiness, request CTD-format dossiers and ask whether documentation is structured to support WHO prequalification submissions.
- Be suspicious of prices far below market — quality has a floor cost.
How Artemisine approaches quality
Our antimalarials are produced in China-GMP workshops re-inspected in 2026, released only after full QC testing against BP / enterprise standards, with retained samples kept one year beyond expiry. Every shipment carries batch COA, and we supply COPP, DMF and CTD dossiers structured to support registration and WHO prequalification submissions.
Source: summarised in plain language from the WHO Guidelines for Malaria (10 September 2026), World Health Organization. This guide is for buyer education only — clinical decisions must follow the locally approved product insert and national treatment guidelines.
